Table 2 Selpercatinib safety overview
From: Therapeutic strategies in RET gene rearranged non-small cell lung cancer
TRAEs with selpercatinib (LOXO-292) | LIBRETTO-001 Safety Database* (N = 531) | |
|---|---|---|
Any | Grade 3 | |
Dry mouth | 27 | – |
Diarrhea | 16 | 1 |
Hypertension | 18 | 8 |
AST increased | 22 | 4 |
ALT increased | 21 | 6 |
Fatigue | 14 | < 1 |
Constipation | 11 | < 1 |
Headache | 7 | < 1 |
Nausea | 8 | < 1 |
Peripheral edema | 10 | – |
Creatinine increased | 10 | – |